Gynecologic Oncology Reports

Our medical research library holds 9 studies published in Gynecologic Oncology Reports (2015–2026). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 9 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Elsevier
• Published: 2013 to the present, Netherlands
• Language: English
• ISSN: 2352-5789 (electronic)
• Continues: Gynecologic Oncology Case Reports
• Its record in the NLM Catalog

2020s

• Government funding for uterine cancer research lags behind rising incidence. R.P. Mojdehbakhsh, R.J. Spencer, N.G. Uczkowski, et al. 2026;65:102107. PubMed · Publisher · Free full text

  Abstract

  Objectives: The second largest government funding source for cancer research is the Department of Defense (DOD). The Peer Reviewed Cancer Research Program (PRCRP) is the funding mechanism for uterine cancer under the DOD. Our objective was to compile cancer research funding granted through the PRCRP by organ site and stratify by incidence of disease to highlight uterine cancer funding.

  Methods: To gather funding information from the PRCRP, a thorough review was done of the CDMRP website, where records of grants funded and the total budgets for the PRCRP had to be manually abstracted from archives.

  Results: Uterine cancer has the second highest incidence of these areas (29.4 per 100,000 in 2021), after colorectal cancer (CRC) (37.5 per 100,000 in 2021). CRC has been funded the longest at 15 years. Mesothelioma, for comparison, has the lowest incidence (0.7 per 100,000 in 2021) and has been funded for 14 years. CRC, with the highest incidence and the longest funded area, has received a total of ∼$60 million through the PRCRP. Mesothelioma, with the lowest incidence and the second longest funded area has received ∼$25 million. Uterine cancer, with the second highest incidence, and one of the shortest funded areas, has received only ∼$14 million. Additionally, the incidence of uterine cancer is rising and has seen a 14.8% increase in incidence from 2009 to 2021 whereas CRC has seen a 15.0% decrease.

  Conclusions: This analysis highlights a proportionate inequity in government funding for uterine cancer when considering the rising incidence of this disease.

  © 2026 The Author(s).

• Malignant peritoneal mesothelioma as a secondary cancer following radiotherapy for cervical cancer: a case report and literature review. M. Otsubo, M. Aichi, Y. Kawashima, et al. 2025;62:101979. Case report PubMed · Publisher · Free full text

  Abstract

  Background: Malignant peritoneal mesothelioma (MPM) as a secondary malignancy following radiotherapy is extremely rare. We report a case of MPM that developed as a secondary malignancy after initial concurrent chemoradiotherapy (CCRT) for cervical cancer.Case Presentation.A 52-year-old woman with no history of asbestos exposure underwent definitive CCRT for stage IIB cervical cancer, as classified by the International Federation of Gynecology and Obstetrics (FIGO) staging system. Over 10 years after initial treatment, she developed ascites. Diagnostic laparoscopy led to a pathological diagnosis of peritoneal mesothelioma. Given the absence of asbestos exposure and her medical history, the tumor was considered a radiation-induced secondary cancer. The patient received two lines of chemotherapy, but her performance status progressively declined, and she was transitioned to best supportive care. She died 1 year and 8 months after the MPM diagnosis.

  Discussion: This case highlights the importance of long-term surveillance following radiotherapy for cervical cancer. Including this case, only four reports exist of MPM developing as a secondary malignancy following pelvic radiotherapy for cervical cancer. In all cases, patients presented with abdominal symptoms and ascites. The case findings underscore the need for clinicians to consider secondary malignancies such as MPM when ascites is detected during follow-up and to pursue a thorough diagnostic workup.

  © 2025 The Authors. Published by Elsevier Inc.

• Malignant STK11 adnexal tumor harboring a somatic mutation in a woman previously diagnosed with mesothelioma, a case report. C.R. Rutherford, T.A. Rives, D.W. Piecoro, et al. 2024;56:101521. Case report PubMed · Publisher · Free full text

  Abstract

  STK11 germline pathogenic variants are typically associated with Peutz-Jeghers syndrome, an autosomal dominant disease characterized by hamartomatous polyps in the gastrointestinal tract, hyperpigmented patches, and increased risk of stomach, colorectal, small bowel, and breast cancers (Beggs et al., 2010). Mutations in this gene have also been identified in skin, pancreatic, testicular, and stromal ovarian cancer (Fagerberg et al., 2014). To date, there have been less than 30 cases of ovarian cancer reported associated with mutated STK11 (Bennett et al., 2021). In this report, we discuss a rare case of a STK11 adnexal tumor in a 39-year-old woman previously diagnosed with malignant mesothelioma. After 33 months with no evidence of disease following cytoreductive surgery with HIPEC and adjuvant chemotherapy, a new retroperitoneal lesion was noted on imaging. After resection, molecular testing indicated an STK11 mutation, and histology was consistent with an STK11 adnexal tumor. A high index of suspicion is required to make the diagnosis of STK11 adnexal tumor due to its non-distinct pathology and IHC staining. Due to the rarity of this neoplasm, analysis of current and future cases of the STK11 adnexal tumor is necessary to understand its pathogenesis, genetic mutational analysis, clinical course, and best treatment options.

  © 2024 The Author(s).

• Peritoneal deciduosis mimicking peritoneal Carcinomatosis: A case report. J. Casanova, J. Jurgiel, V. Henriques, et al. 2021;37:100827. Case report PubMed · Publisher · Free full text

  Abstract

  Ectopic decidual reaction (or deciduosis) can be rarely seen in the peritoneum and most of the cases in the literature are associated with pregnancy. It is more commonly found in the ovaries, uterus and cervix. Although its pathophysiology is not totally understood, it is accepted that peritoneal deciduosis develops as a result of the progesterone induced metaplasia of subserosal stromal cells during pregnancy. It is important to distinguish this entity from oncologic conditions, namely metastatic carcinoma and mesothelioma. We report an unusual case of a 40 year-old non pregnant patient that presented with imaging findings suggestive of peritoneal carcinomatosis.

  © 2021 The Author(s).

• A case of sarcomatoid malignant peritoneal mesothelioma diagnosed by laparoscopy. M. Kobayashi, K. Masuda, Y. Noda, et al. 2020;34:100642. Case report PubMed · Publisher · Free full text

  Abstract

  •Malignant peritoneal mesothelioma, particularly the sarcomatoid type, is rare and aggressive.•Accurate diagnosis by ascites cytology is difficult.•Histological examination such as laparoscopy aids in diagnosis.•There is no clear consensus treatment for MPM and an extensive research program is needed.

  © 2020 The Authors.

2010s

• Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. L. Losi, L. Botticelli, G. Taccagni, et al. 2018;24:39-42. Case report PubMed · Publisher · Free full text

  Abstract

  We report a case of a 59-year-old woman with peritoneal malignant mesothelioma and no previous exposure to asbestos with a diagnosis of bilateral ovarian serous borderline tumour with peritoneal implants one year before. We discuss the histopathological and immunohistochemical findings to explain possible and potential interactions between the two diseases. To our knowledge, the association of both serous borderline ovarian tumour and malignant peritoneal mesothelioma has never been described before in the same woman and in such a tight temporal connection. This finding raises numerous issues about the origin of the two tumours and further biomolecular studies are needed to fully understand the carcinogenetic process. From a clinical point of view, this case report can be useful to gynaecologists because it leads to recommend a careful examination of the peritoneal cavity during a surgical resection of borderline serous tumour. Moreover, it may suggest performing a close follow-up associated with a careful surveillance of the patient, especially in the case of micropapillary pattern, to oncologists. A complete clinical approach could help to detect sooner possible relapses or other metachronous malignancies.

• Incidental fallopian tube mesothelioma diagnosed at time of elective bilateral salpingectomy for sterilisation: A case report. J. Phillips-Yelland, D. Payton, R. Land, et al. 2017;22:1-3. Case report PubMed · Publisher · Free full text

  Abstract

  •Incidental finding of a fallopian tube lesion at the time of bilateral salpingectomy•Histopathological appearance not consistent with mucinous or serous carcinoma, appearance of mesothelioma•Very rare known primary neoplasm of tubal mesothelium, favours an indolent course•Recommendation for prophylactic hysterectomy and bilateral oophorectomy•If nil further spread, generally nil further treatment is required.

• A case of mesothelioma masquerading pre-operatively as ovarian cancer and brief review of the literature. K.L. Hancock, C.M. Clinton, H.E. Dinkelspiel, et al. 2016;17:26-8. Case report PubMed · Publisher · Free full text

  Abstract

  Background: Malignant peritoneal mesothelioma (MPM) can masquerade as an ovarian epithelial neoplasm, with very similar presenting clinical symptoms and imaging findings. The gold standard in differentiating between these two diagnoses lies in tissue pathology.

  Case Report: This is a case of MPM that was initially misdiagnosed as ovarian cancer based on family history, imaging, and surgical findings. Tissue diagnosis preoperatively would have changed the planned procedure. Retrospectively, after the diagnosis of MPM, the patient was found to have had an indirect exposure to asbestos through her father.

  Conclusions: This case highlights the importance of keeping a broad differential when diagnosing ovarian malignancies, collecting both family and social histories (including screening for exposure to asbestos), and the benefit of obtaining tissue diagnosis when MPM is suspected.

• Malignant peritoneal mesothelioma without asbestos exposure: An ovarian cancer imitator. K.S. Grzankowski, R.M. Brightwell, J.M. Kasznica, et al. 2015;11:10-2. Case report PubMed · Publisher · Free full text

  Abstract

  •Malignant peritoneal mesothelioma is a rare aggressive tumor with approximately 400 new cases annually in the US.•In optimal cytoreduction HIPEC is the standard treatment.•In suboptimal cytoreduction IV cisplatin and pemetrexed have high efficacy.

Browse every journal in the library or the library by type of article, or return to medical research.